BACKGROUND: Hepatitis E virus (HEV) has been found to be the causative agent of enterically transmitted non-A, non-B hepatitis in tropical and subtropical countries. Several investigators, however, have indicated that HEV could be endemic in Europe, albeit at a low prevalence. STUDY DESIGN AND METHODS: The purpose of this study was to estimate the prevalence of anti-HEV in various populations in northwestern Greece (Epirus region). Healthy blood donors (2636), refugees from southern Albania (350), children (165), injecting drug users (IDUs) (65), multiply transfused patients (62), patients with chronic viral hepatitis (75), and chronic hemodialysis patients (149) were investigated for anti-HEV by enzyme immunoassay and confirmatory Western blot assay. In addition, 380 consecutive healthy blood donors and 62 hemodialysis patients from a neighboring area (Agrinion, Greece) were investigated. RESULTS: A very low presence of anti-HEV antibody was found among healthy blood donors from Epirus (0.23%) and Agrinion (0.53%). Anti-HEV was not detected in children, IDUs, or multiply transfused patients. In contrast, a low but significant prevalence of anti-HEV was found among refugees (4.85%), patients with chronic viral hepatitis (5.3%), and hemodialysis patients from Epirus (1.34%), as compared with healthy blood donors from Epirus: p < 0.0001, p < 0.00001, and p < 0.10, respectively. A high prevalence (9.7%) of anti-HEV was revealed in patients at the hemodialysis unit of the General Hospital of Agrinion (p < 0.00005, compared to healthy blood donors from Agrinion). No significant association was found between anti-HEV positivity and the age or sex of donors, the duration of hemodialysis, positivity for hepatitis B or C virus infection markers, history of hepatitis, increased alanine aminotransferase, renal transplantation, a history of transfusion, or the number of units transfused. CONCLUSION: This study demonstrated a high prevalence of anti-HEV in a separate hemodialysis unit, without an association with the known routes of transmission of blood-borne viruses. This observation suggests that a still-undefined intra-unit factor or other factors are associated with HEV transmission.
BACKGROUND:Hepatitis E virus (HEV) has been found to be the causative agent of enterically transmitted non-A, non-B hepatitis in tropical and subtropical countries. Several investigators, however, have indicated that HEV could be endemic in Europe, albeit at a low prevalence. STUDY DESIGN AND METHODS: The purpose of this study was to estimate the prevalence of anti-HEV in various populations in northwestern Greece (Epirus region). Healthy blood donors (2636), refugees from southern Albania (350), children (165), injecting drug users (IDUs) (65), multiply transfused patients (62), patients with chronic viral hepatitis (75), and chronic hemodialysis patients (149) were investigated for anti-HEV by enzyme immunoassay and confirmatory Western blot assay. In addition, 380 consecutive healthy blood donors and 62 hemodialysis patients from a neighboring area (Agrinion, Greece) were investigated. RESULTS: A very low presence of anti-HEV antibody was found among healthy blood donors from Epirus (0.23%) and Agrinion (0.53%). Anti-HEV was not detected in children, IDUs, or multiply transfused patients. In contrast, a low but significant prevalence of anti-HEV was found among refugees (4.85%), patients with chronic viral hepatitis (5.3%), and hemodialysis patients from Epirus (1.34%), as compared with healthy blood donors from Epirus: p < 0.0001, p < 0.00001, and p < 0.10, respectively. A high prevalence (9.7%) of anti-HEV was revealed in patients at the hemodialysis unit of the General Hospital of Agrinion (p < 0.00005, compared to healthy blood donors from Agrinion). No significant association was found between anti-HEV positivity and the age or sex of donors, the duration of hemodialysis, positivity for hepatitis B or C virus infection markers, history of hepatitis, increased alanine aminotransferase, renal transplantation, a history of transfusion, or the number of units transfused. CONCLUSION: This study demonstrated a high prevalence of anti-HEV in a separate hemodialysis unit, without an association with the known routes of transmission of blood-borne viruses. This observation suggests that a still-undefined intra-unit factor or other factors are associated with HEV transmission.
Authors: Maria Buti; Angela Domínguez; Pere Plans; Rossend Jardí; Mélani Schaper; Jordi Espuñes; Neus Cardeñosa; Francisco Rodríguez-Frías; Rafael Esteban; Antoni Plasència; Luis Salleras Journal: Clin Vaccine Immunol Date: 2006-10-18
Authors: L A Kondili; P Chionne; A Porcaro; E Madonna; S Taffon; B Resuli; G Taliani; M Rapicetta Journal: Epidemiol Infect Date: 2006-02 Impact factor: 2.451
Authors: Tauseef Ahmad; Saima Nasir; Taha Hussein Musa; Saif Aldeen S AlRyalat; Muhammad Khan; Jin Hui Journal: Hum Vaccin Immunother Date: 2020-08-05 Impact factor: 3.452
Authors: Paraskevi Mina; Sarah P Georgiadou; Christos Rizos; George N Dalekos; Eirini I Rigopoulou Journal: World J Gastroenterol Date: 2010-01-14 Impact factor: 5.742
Authors: Anna Mrzljak; Petra Dinjar-Kujundzic; Mladen Knotek; Boris Kudumija; Mario Ilic; Marijana Gulin; Lada Zibar; Irena Hrstic; Zeljka Jurekovic; Branko Kolaric; Lorena Jemersic; Jelena Prpic; Morana Tomljenovic; Tatjana Vilibic-Cavlek Journal: Int Urol Nephrol Date: 2020-01-01 Impact factor: 2.370
Authors: Kuan Abdoulaye Traoré; Hortense Rouamba; Yacouba Nébié; Mahamadou Sanou; Alfred S Traoré; Nicolas Barro; Pierre Roques Journal: PLoS One Date: 2012-10-22 Impact factor: 3.240